In a syngeneic setting, CD8+ CTL have been shown to effectively combat patient tumor cells in immunodeficient mice (125, 126), and such models may help to identify tumor rejection antigens and T cell receptors for redirecting immunity to tumors in a patient-individualized manner. This evidence concerns the gene CD8A and neoplasm.